放射性碘:一部活的历史
本文回顾放射性碘(RAI)从1936年提出设想到1942年用于治疗Graves甲亢、1948年证实促甲状腺激素可刺激甲状腺癌转移灶摄碘的历史,并指出目前RAI在Graves甲亢和甲状腺癌中的应用趋于选择性,其未来因Graves病抗体抑制和基因靶向治疗而存在不确定性。
要点
- 1942年Hertz和Roberts报告成功使用放射性碘治疗Graves甲亢。
- 1990年北美69%的内分泌科医生推荐放射性碘用于Graves甲亢。
- 目前放射性碘用于Graves甲亢减少,与担心甲状腺眼病加重、辐射暴露和永久性甲减有关。
核心结论
- 放射性碘是医师与科学家机构间合作在仅三年内实现从实验室到临床转化的杰出范例。
- 放射性碘是疾病诊疗一体化方法(同时使用放射性药物进行诊断和治疗)的模型。
- 放射性碘的未来不太确定;抑制Graves病中的促甲状腺激素受体刺激抗体以及更精确靶向驱动甲状腺肿瘤发生的基因可能减少放射性碘的使用。
- 或者,再分化技术可能提高放射性碘在放射性碘难治性甲状腺癌中的疗效。
研究设计与样本
- 本文为历史综述,回顾放射性碘的发展历程及相关临床应用变迁。
主要发现
- 在20世纪40年代抗甲状腺药物开发之前,Graves甲亢的治疗主要是手术,手术死亡率变化相当大,但相当一部分患者在术中或术后死亡。
- 1936年,麻省理工学院院长Karl Compton在一次有麻省总医院医生参加的讲座中提出,人工放射性同位素可能有助于研究代谢。
- 到1942年,Hertz和Roberts报告了成功使用放射性碘治疗Graves甲亢。
- 随后在分化良好的甲状腺癌转移灶中证实了放射性碘摄取。
- 1948年,Seidlin证实促甲状腺激素(TSH)可刺激甲状腺癌转移灶的摄取。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Before the development of antithyroid drugs in the 1940s, treatment of Graves' hyperthyroidism was primarily surgical. Surgical mortality was quite variable, but a significant minority of patients died during or after surgery. Summary: In 1936, Karl Compton, President of the Massachusetts Institute of Technology, in a lecture attended by Massachusetts General Hospital physicians, suggested that artificially radioactive isotopes might be useful for studying metabolism. By 1942, Hertz and Roberts reported on the successful use of radioactive iodine (RAI) to treat Graves' hyperthyroidism. RAI uptake was subsequently demonstrated in well-differentiated thyroid cancer metastases. In 1948, Seidlin demonstrated stimulation of uptake in thyroid cancer metastases by thyrotropin (TSH). By 1990, 69% of endocrinologists in North America recommended RAI for Graves' hyperthyroidism. Currently RAI is less frequently used for Graves' hyperthyroidism, related to concerns about exacerbation of thyroid eye disease, about radiation exposure, and about potential adverse consequences of permanent hypothyroidism. Similarly, RAI was administered to the majority of patients with thyroid cancer for decades, but its use is now more selective. Conclusions: RAI is a remarkable example of interinstitutional cooperation between physicians and scientists to transition from bench to bedside in only three years. It is the model for a theranostic approach to disease (the simultaneous use of a radioactive drug for diagnosis and therapy). The future of RAI is less certain; inhibition of TSH receptor stimulating antibodies in Graves' disease and more precise targeting of genes that drive thyroid oncogenesis may diminish the use of RAI. Alternatively, redifferentiation techniques may improve the efficacy of RAI in RAI-refractory thyroid cancer.
引用
- Daniels GH, Ross DS. Radioactive Iodine: A Living History. Thyroid. 2023. PMID: 37307104. doi:10.1089/thy.2022.0344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。